Phase 1 Refractory Systemic Lupus Erythematosus Clinical Trials
4 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–4 of 4 trials
Recruiting
Phase 1
NK010 or NK042 in Combination With Rituximab for Refractory Systemic Lupus Erythematosus/Lupus Nephritis
Refractory Lupus NephritisRefractory Systemic Lupus Erythematosus
Guangdong Provincial People's Hospital18 enrolled1 locationNCT06676631
Recruiting
Phase 1Phase 2
A Study of GC012F Injection in Subjects With Refractory Systemic Lupus Erythematosus
Refractory Systemic Lupus Erythematosus
Gracell Biotechnologies (Shanghai) Co., Ltd.118 enrolled2 locationsNCT06530849
Recruiting
Phase 1Phase 2
SELECT-SLE: Biomarker-Guided CAR-T Target Selection for Refractory Lupus
Lupus NephritisRefractory Systemic Lupus Erythematosus
Beijing Biotech24 enrolled1 locationNCT07523542
Recruiting
Phase 1
Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases
Relapsed/Refractory Systemic Lupus ErythematosusRelapsed/Refractory Systemic SclerosisRelapsed/Refractory Idiopathic Inflammatory Myopathies+3 more
Beijing Boren Hospital12 enrolled1 locationNCT07361094